Validity of self-reported mammography uptake in the Belgian health interview survey : selection and reporting bias by Berete, Finaba et al.
European Journal of Public Health, 1–7
 The Author(s) 2020. Published by Oxford University Press on behalf of the European Public Health Association.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/),
which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
doi:10.1093/eurpub/ckaa217
. . . .. . . .. . .. . . .. . . .. . .. . . .. . .. . . .. . . .. . .. . . .. . . .. . .. . . .. . . .. . .. . . .. . .. . . .. . . .. . .. . . .. . . .. . .. . . .. . . .. . .. . .
Validity of self-reported mammography uptake in
the Belgian health interview survey: selection and
reporting bias
Finaba Berete1,2*, Johan Van der Heyden1, Stefaan Demarest1, Rana Charafeddine1,
Jean Tafforeau1, Herman Van Oyen1,3, Olivier Bruyère4, Françoise Renard1
1 Department Epidemiology and Public Health, Sciensano, Brussels, Belgium
2 Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium
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Background: The validity of self-reported mammography uptake is often questioned. We assessed the related
selection and reporting biases among women aged 50–69 years in the Belgian Health Interview Survey (BHIS)
using reimbursement data for mammography stemming from the Belgian Compulsory Health Insurance organ-
izations (BCHI). Methods: Individual BHIS 2013 data (n¼ 1040) were linked to BCHI data 2010–13 (BHIS–BCHI
sample). Being reimbursed for mammography within the last 2-years was used as the gold standard. Selection
bias was assessed by comparing BHIS estimates reimbursement rates in BHIS–BCHI with similar estimates from the
Echantillon Permanent/Permanente Steekproef (EPS), a random sample of BCHI data, while reporting bias was
investigated by comparing self-reported versus reimbursement information in the BHIS–BCHI. Reporting bias was
further explored through measures of agreement and logistic regression. Results: Mammography uptake rates
based on self-reported information and reimbursement from the BHIS–BCHI were 75.5% and 69.8%, respectively.
In the EPS, it was 64.1%. The validity is significantly affected by both selection bias frelative size¼ 8.93% [95%
confidence interval (CI): 3.21–14.64]g and reporting bias [relative size¼8.22% (95% CI: 0.76–15.68)]. Sensitivity
was excellent (93.7%), while the specificity was fair (66.4%). The agreement was moderate (kappa¼0.63).
Women born in non-EU countries (OR¼ 2.81, 95% CI: 1.54–5.13), with high household income (OR¼ 1.27, 95%
CI: 1.02–1.60) and those reporting poor perceived health (OR¼ 1.41, 95% CI: 1.14–1.73) were more likely to
inaccurately report their mammography uptake. Conclusions: The validity of self-reported mammography uptake
in women aged 50–69 years is affected by both selection and reporting bias. Both administrative and survey data
are complementary when assessing mammography uptake.
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Introduction
B
reast cancer is the most common cancer in terms of incidence
among women both in developed and developing countries1–3
and the second cause of cancer death among women after lung
cancer in most developed countries.4
Early detection of breast cancer through mammography screening
is recognized as being effective in reducing mortality5,6; in women
aged 50–69 years.7–9 Literature suggests that with a screening attend-
ance reaching 70%, a reduction in breast cancer mortality by about
25% might be expected.8,10 European guidelines recommend bien-
nial mammography screening for women aged 50–69 years.11
Valid methods of determining and monitoring breast cancer
screening (screening) uptake are important to evaluate screening
programs.6,12,13 Underestimating screening prevalence could lead
to waste of resources, while overestimation could lead to missed
opportunities for improving screening.6
Currently, information on screening is often based on self-reports
in population-based surveys.5,6,12,13 Such information is used to
monitor screening rates over time and to target interventions.
However, the validity of self-reported information through surveys
is a concern due to a potential selection (because of non-coverage or
non-response error) and reporting bias associated with differential
survey participation. Survey participants may systematically differ
from the general population and reporting may be inaccurate due
to memory and social desirability effects. The validity can also be
different for different subpopulations. For example, it has been
shown that members of ethnic minority groups and people with a
lower socioeconomic status are more likely to inaccurately report
cancer screening than their counterparts.5,13,14
According to the European screening quality assurance guidelines,
the acceptable and desirable participation rates of screening are 70%
and 75%, respectively.9 Furthermore, the European Partnership for
Action Against Cancer called for reducing the burden of cancer by
achieving 100% population coverage of screening for breast, cervical
and colorectal cancer in 2013.15,16 In the USA, the Healthy People
2020 goals calls for a rate of adherence to national cancer-screening
guidelines of 81% biannual mammography among women aged 50–
74 years.17,18
To verify whether these goals are met, it is necessary to ensure that
the data for estimating the national mammography uptake rate are
valid.
The validity of self-reported mammography uptake can be veri-
fied by comparing this information with a trusted measure (gold
standard). Numerous validation studies and meta-analyses have
documented the level of agreement/disagreement between self-
reported cancer screening and cancer registers, claims databases,
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have reported a sensitivity between 95% and 97%, a specificity be-
tween 61% and 64% and have concluded that the estimates based on
self-report are usually over-estimated.5,12 However, most of these
validation studies are either limited to a specific geographical re-
gion6,19–21 or a specific subgroup13,14, leading to a problem of
generalizability.
In Belgium, breast cancer is the first female cancer in terms of
incidence (more than a third of cancers)22 and the leading cause of
premature death among women.23
A national mammography screening program exists in Belgium
since 2001–02. Mammograms realized within this organized screen-
ing program are called ‘mammotests’. Such mammograms are en-
tirely reimbursed by the National Institute of Health and Disability
Insurance (NIHDI) as well as diagnostic mammograms (i.e. among
symptomatic women or those at high-risk). The mammotests and
diagnostic mammograms are coded differently in the BCHI data-
base. Besides the mammotests, a number of screening was often
realized by women outside of the official screening program (by
their own initiative). These later are called ‘opportunistic screening’
and are not reimbursed by the NIHDI. More often, for the reim-
bursement purposes, the opportunistic screening is miscoded as
diagnostic mammograms. The proportion of mammograms realized
outside of the screening program is important. Thus, information
on mammography uptake gathered through the BCHI data allow to
capture the total coverage of the screening than those through the
official screening program. Each woman aged 50–69 years receives
every 2 years an invitation to participate in the screening program.
The mammograms realized within the program follow a specific
procedure. The examination is free of charge.24 Exhaustive informa-
tion on the mammography uptake is available through the Belgian
Compulsory Health Insurance (BCHI) including both mammo-
grams realized within and outside the organized screening pro-
gram.25 However, the BCHI database is limited in terms of socio-
demographic information.
Information on mammography uptake (‘having had mammo-
grams’), based on self-reports is available in the Belgian Health
Interview Survey (BHIS).26 The added value of the BHIS data is
that it provides a comprehensive information on socioeconomic
status (SES) and many other health-related topics useful for sub-
group analyzes. Nevertheless, as in other population surveys, selec-
tion and reporting bias are also a concern in the BHIS.27 In this
study, we investigate the validity of self-reported mammography
attendance in the BHIS, as a proxy of screening uptake by assessing
the associated selection and reporting biases.
Methods
Data sources
BHIS 2013 data were linked to BCHI 2010–2013 data (BHIS–BCHI)
by means of a unique identifier (the national register number). The
BHIS is a national, cross-sectional household survey conducted
every 5 years since 1997 by Sciensano among a representative sample
of Belgian residents. Participants are selected from the national
population register through a multistage stratified sampling proced-
ure. The detailed methodology of the survey is described
elsewhere.28
The BHIS collects information on mammography uptake by
means of a self-administered questionnaire in women aged 15 years
and older (the reference population of Eurostat, although the main
indicator refers to women aged 50–69 years): Have you ever had
mammograms? ‘Yes/No’ and for those who respond ‘Yes’, the
time lapse since her last mammograms: ‘When was the last time
you had mammograms?’ Furthermore, the BHIS also collects data
on a wide range of other health and health-related topics such as
demographic information, SES and self-reported health status, life
style and health services use. The BHIS has been approved by the
ethics committee of the University hospital of Ghent on 1 October
2012 (advice EC UZG 2012/658). For the linkage, an authorization
was obtained from the Belgian Privacy Commission.
BCHI data contain exhaustive and detailed information on the
reimbursed health expenses of over 99% of the total population. The
database also includes a limited amount of socio-demographic
information.29
The Echantillon Permanent/Permanente Steekproef (EPS) data,
representing 1/40 of the Belgian population, is an unbiased random
sample of the BCHI and contains the same information as the BCHI
(reimbursed medical acts, hospitalization and medicines) which is
also followed over time. The use the data of this population cohort
in an anonymized way for policy and research purposes is regulated
by a specific legal framework.27 All women aged 50–69 years within
the EPS are included in this study. The analysis of the EPS data does
not require any design settings.
Inclusion criteria
This study included women aged 50–69 years who responded to the
questions related to the mammography uptake ‘having had mam-
mograms’ of BHIS (n¼ 1081). Linkage with BCHI was possible for
1040 women (96%). To assess the validity of self-reported mam-
mography uptake, reimbursement for a mammography within the
last 2 years preceding the BHIS was used as the gold standard. As nor
in BHIS nor in BCHI it is not possible to disentangle mammograms
realized within the screening program from opportunistic screening,
both types are included in this study. We assume that in both
sources, the mammography uptake in this age-group is a good proxy
for the screening uptake.
Analyses
Mammography uptake rates by data source were calculated.
Selection bias
The potential selection bias was computed as the difference between
the prevalence of register within BCHI based mammography uptake
from the BHIS–BCHI and similar estimates from the EPS data (ab-
solute bias), and dividing that difference by the prevalence from the
EPS data and multiplied by 100 (relative bias).30 The 95% CI of the
estimated bias was computed using the Delta method.29 Analyses
were done overall and by age-group and region of residence.
Reporting bias
The reporting bias was assessed as the difference in the prevalence of
mammography uptake between BHIS and BCHI estimates from the
BHIS–BCHI linked data. As for the selection bias, both absolute and
relative percentages were calculated. Next, the report-to-record ratio
(RRR) was computed. The RRR is the ratio of the percentage of
women reporting having had mammograms to the percentage of
women reimbursed for mammograms during the relevant time
period, and its confidence intervals. The RRR is frequently used as
a measure of net bias of self-report, with values greater than one
indicating over-reporting and values less than one indicating under-
reporting.6,13,31,32 Furthermore, the sensitivity (i.e. the percentage of
women classified as screened in the BHIS among those who were
reimbursed for mammograms in the BCHI), the specificity (i.e. the
percentage of women classified as not screened in the BHIS, among
those who were not reimbursed for mammograms in the BCHI), the
positive predictive value (PPV, i.e. the percentage of women reim-
bursed for mammograms in the BCHI, among those classified as
screened in the BHIS) and the negative predictive value (NPV, i.e.
the percentage of women who were not reimbursed for mammo-
grams in the BCHI, among those who were classified as not screened
in the BHIS) were calculated. These estimates were classified as ex-
cellent (>0.90), good (>0.80), fair (>0.70) or poor (<0.70).33
Sensitivity analysis was performed by moving the time frame for
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screening from 2 to 3 years. The total agreement as well as the
Cohen’s kappa statistic were also calculated to provide a measure
of agreement beyond chance.34 Cutoffs used to classify kappa are
based on McHugh et al.: 0–0.20¼ none agreement; 0.21–
0.39¼minimal agreement; 0.40–0.59¼weak agreement; 0.60–
0.79¼moderate agreement; 0.80–0.90¼ strong agreement; above
0.90¼ almost perfect agreement.35
The calculations were done for the whole population and by
socio-demographic subgroups; by age-group (50–59 years, 60–
69 years), educational level, country of birth (Belgium, other EU
country, non-EU country), region of residence (Flanders, Brussels
and Wallonia), income category (low, high) and self-perceived
health (good to very good, very bad to fair). Educational level was
based on the highest level of education achieved in the household
according to the ISCED 199736 and recoded into three categories:
low (lower secondary education or less), intermediate (higher sec-
ondary education) and high (higher education). For income level,
the quintiles of the equivalent household income were recoded in
low (quintile 1–3) and high (quintile 4 and 5). As this is an explora-
tory and post-hoc analysis of existing data, a strict adjustment for
multiple comparisons is less critical.37 Therefore, we declined to
adjust for multiple comparisons.
Finally, multivariable logistic regression was used to identify cova-
riates associated with inaccurate self-reported mammography up-
take (over- or under-reporting). All variables cited above were
included as independent variables. In order to maximize the infor-
mation available in the analyses and to prevent potential bias caused
by selective drop out, item non-response for education, household
income, perceived health and place of birth (item missingness be-
tween 1% and 10%) was addressed by multiple imputations. Age,
region of residence, as well as the dependent variable were used in
the imputation model. The dependent variable (3.5% of missing-
ness) was included in the imputation model in order to enhance it
and was reliably imputed. However, its imputed values were not
used in the analysis model. Multivariate normal regression was
used as the imputation method to estimate missing values.38
Survey data were analyzed taking into account the multistage strati-
fied clustered sampling design of the BHIS: use of post stratification
weights, geographical stratification at the level of the province and
clustering at household level. Statistical significance was defined as
P< 0.05. Potential selection and reporting bias were estimated using
Stata 15.1. All the remaining analyses were performed using SAS
9.4.
Results
Table 1 presents the prevalence of mammography uptake by data
source and subgroups. Based on the BHIS–BCHI, the mammog-
raphy uptake in the BHIS 2013 sample was estimated to be 75.5%
using BHIS information and 69.8% using BCHI information.
Within the EPS, the percentage was 64.1%. The percentage also
varies significantly across subgroups in both data sources.
Table 2 summarizes both the selection and reporting biases. A
significant difference between the BHIS–BCHI and the EPS mam-
mography uptake reimbursement rates is observed overall. The ab-
solute and relative size of the selection bias is 5.72% points (95% CI:
2.06–9.38) and 8.93% (95% CI: 3.21–14.64), respectively. No sig-
nificant differences were detected between subgroups.
Also, for the reporting bias, a significant difference between self-
reported and reimbursement information in the BHIS–BCHI is
observed. The absolute size is 5.74% points (95% CI: 0.75–10.7)
and the relative size is 8.22% (95% CI: 0.76–15.68), respectively. A
subgroup analyses indicates that the mammography uptake is over
reported by 14% for women aged 50–59 years, 11% for those highly
educated, 8% for women born in Belgium and 23% for those resid-
ing in Wallonia. This over-reporting is confirmed by the RRR in the
related subgroups.
Table 3 reports the more common measures of agreement related
to the reporting bias. The sensitivity was excellent overall (93.7%)
and across subgroups except for women born in other EU countries
and for those reporting a poor perceived health; whereas the speci-
ficity was poor (66.4%) overall and did not exceed 70% in most of
the subgroups. When the time frame was moved from 2 to 3 years,
the specificity increased to 83%. The overall agreement was 84%
(result not shown) and the kappa statistics was 0.63. The PPV was
Table 1 Prevalence of mammography uptake in the last 2 years, by source and subgroups, Belgium 2013
BHIS–BCHI linked (n 5 1040) EPS (n 5 36 700)
BHIS BCHI
% uptake 95% CI % uptake 95% CI % uptake 95% CI
Overall 75.5 (72.1–78.9) 69.8 (66.2–73.4) 64.1 (63.6–64.6)
Age (years)
50–59 78.0 (73.6–82.4) 68.6 (63.6–73.6) 67.1 (66.4–67.7)
60–69 72.8 (67.6–77.9) 71.1 (65.8–76.3) 67.0 (66.3–67.8)
Educational level NA
Low 66.2 (59.4–73.1) 61.0 (53.5–68.4)
Middle 76.4 (70.3–82.4) 73.4 (67.1–79.6)
High 81.7 (76.9–86.4) 73.7 (68.2–79.2)
Place of birth NA
Belgium 76.0 (72.4–79.5) 70.1 (66.3–73.9)
EU country 63.2 (50.1–76.3) 57.5 (44.0–71.1)
Non-EU country 82.7 (66.8–98.6) 81.0 (65.0–97.0)
Region
Flanders 78.0 (73.4–82.6) 76.1 (71.2–80.9) 71.2 (70.6–71.8)
Brussels 75.8 (68.4–83.2) 66.7 (58.5–74.9) 59.3 (57.40–61.2)
Wallonia 70.3 (64.9–75.6) 57.3 (51.4–63.2) 61.8 (61.0–62.8)
Income NA
Low 71.9 (66.6–77.1) 66.2 (60.7–71.6)
High 79.4 (74.5–84.3) 74.6 (69.2–80.0)
Health status NA
Good to very good 79.7 (75.8–83.6) 74.0 (69.7–78.2)
Very bad to fair 65.0 (58.6–71.3) 58.6 (51.8–65.4)
BHIS, Belgian Health Interview Survey; BCHI, Belgian Compulsory Health Insurance; EPS, Permanent Sample (random sample of the Belgian
Compulsory Health Insurance data); NA, Not available.
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Table 2 Estimated bias in mammography uptake in the last 2 years among women aged 50–69 years in the BHIS–BCHI linked sample,
Belgium 2013
Estimated biasa
Selection biasb (%) Reporting biasc (%)
Absoluted (95% CI) Relativee (95% CI) Absolutef (95% CI) Relativeg (95% CI) RRR (95% CI)
Overall 5.72 (2.06–9.38)* 8.93 (3.21–14.64)* 5.74 (0.75–10.72)* 8.22 (0.76–15.68)* 1.08 (1.02–1.15)*
Age (years)
50–59 1.56 (3.50–6.62) 2.32 (5.23–9.87) 9.42 (2.67–16.17)* 13.72 (3.12–24.33)* 1.14 (1.05–1.23)*
60–69 4.04 (1.27–9.34) 6.02 (1.91–13.95) 1.67 (0.57–9.06) 2.35 (8.16–12.87) 1.02 (0.94–1.11)
Educational level N.Ah
Low 5.22 (5.09–15.53) 8.56 (9.11–26.23) 1.09 (0.95–1.24)
Middle 2.99 (5.67–11.65) 4.08 (7.97–16.12) 1.04 (0.95–1.14)
High 7.98 (0.62–15.34)* 10.83 (0.22–21.45)* 1.11 (1.02–1.21)*
Place of birth N.Ah
Belgium 5.86 (0.63–11.10)* 8.36 (0.56–16.17)* 1.08 (1.02–1.15)*
EU country 5.67 (14.66–26.01) 9.86 (27.25–46.97) 1.10 (0.90–1.34)
Non-EU country 1.70 (19.67–23.07) 2.10 (24.54–28.74) 1.02 (0.83–1.25)
Region N.Ah
Flanders 4.86 (0.03–9.75) 6.82 (0.06–13.70) 1.95 (4.75–8.66) 2.57 (6.36–11.50) 1.03 (0.95–1.11)
Brussels 7.43 (0.89–15.75) 12.53 (1.60–26.67) 9.12 (1.83–20.01) 13.67 (4.00–31.34) 1.14 (1.00–1.29)
Wallonia 4.56 (10.51–1.38) 7.38 (16.98–2.22) 12.95 (5.01–20.89)* 22.60 (6.95–38.25)* 1.23 (1.10–1.36)*
Income N.Ah
Low 5.69 (1.86–13.25) 8.61 (3.33–20.54) 1.09 (0.99–1.19)
High 4.82 (2.54–12.19) 6.46 (3.76–16.69) 1.05 (0.97–1.13)
Health status N.Ah
Good to very good 5.69 (0.07–11.44) 7.69 (0.41–15.79) 1.08 (1.01–1.15)
Very bad to fair 6.41 (3.15–15.98) 10.96 (6.32–28.23) 1.11 (0.98–1.26)
a: Computed before rounding the percentages.
b: Computed by comparing the percentage of women with a mammography reimbursement in the BHIS–BCHI linked sample and in the EPS
data.
c: Computed by comparing the percentage of self-reported mammography uptake and mammography reimbursement in the BHIS–BCHI
linked data.
d: Absolute difference in the prevalence of mammography reimbursement rates in the BHIS–BCHI linked sample and similar estimates from
the EPS data.
e: Relative excess in percentage, computed as the differences between the percentage of women with a mammography reimbursement in
the BHIS–BCHI linked sample and in the EPS data, divided by the percentage from the EPS data.
f: Absolute difference in the prevalence of self-reported mammography uptake and reimbursement rate in the BHIS–BCHI linked data.
g: Relative excess in percentage, computed as the difference between the percentage of self-reported mammography uptake and mam-
mography reimbursement in the BHIS–BCHI linked data, divided by the percentage of reimbursement in the BHIS–BCHI linked data.
h: N.A ¼ Not available.
*: Significant result (P<0.05).
Table 3 Measures of validity of self-reported mammography uptake using administrative data as gold standard (BHIS–BCHI linked), Belgium
2013
Characteristics Sensitivity (%) Specificity (%) Positive predictive value (%) Negative predictive value (%) Kappa statistic
Overall 93.7 (91.5–95.9) 66.4 (59.7–73.1) 86.6 (83.5–89.6) 82.0 (76.2–87.8) 0.63 (0.58–0.68)
Age (years)
50–59 95.9 (93.1–98.6) 61.0 (51.5–70.4) 84.3 (79.9–88.7) 87.1 (78.9–95.3) 0.63 (0.56–0.70)
60–69 91.4 (87.8–94.9) 73.0 (64.0–81.9) 89.3 (85.3–93.3) 77.4 (68.9–85.9) 0.64 (0.56–0.71)
Education
Low 98.4 (84.1–94.7) 70.0 (58.9–81.1) 82.3 (75.2–89.5) 80.8 (71.1–90.6) 0.60 (0.50–0.70)
Middle 92.1 (87.7–96.4) 66.9 (54.1–79.7) 88.5 (83.6–93.3) 75.4 (62.1–88.7) 0.59 (0.50–0.69)
High 97.5 (95.0–99.9) 62.6 (50.7–74.5) 87.9 (83.3–92.6) 89.8 (80.7–98.9) 0.70 (0.62–0.78)
Place of birth
Belgium 93.8 (91.4–96.1) 65.7 (58.6–72.8) 86.5 (83.3–89.7) 81.8 (75.6–88.0) 0.64 (0.58–0.69)
EU countries 88.0 (78.1–97.8) 70.4 (50.3–90.5) 80.1 (66.0–94.2) 81.2 (64.6–97.9) 0.53 (0.34–0.72)
Non-EU country 99.0 (96.9–100) 86.7 (67.9–100) 96.9 (92.9–100) 95.2 (83.8–100) 0.77 (0.55–0.98)
Region
Flanders 92.6 (89.6–95.7) 68.4 (57.5–79.3) 90.3 (86.5–94.1) 74.5 (64.7–84.2) 0.61 (0.52–0.70)
Brussels 98.5 (96.7–100) 69.6 (55.7–83.5) 86.7 (80.0–93.3) 95.9 (90.9–100) 0.72 (0.62–0.83)
Wallonia 95.5 (92.8–98.1) 63.6 (54.8–72.3) 77.9 (71.9–83.8) 91.3 (86.2–96.4) 0.60 (0.53–0.67)
Income category
Low 93.7 (90.3–97.1) 70.9 (62.7–79.0) 86.3 (82.0–90.5) 85.2 (77.5–92.9) 0.64 (0.57–0.71)
High 93.6 (90.3–96.9) 62.2 (49.5–74.9) 87.9 (83.2–92.6) 76.7 (67.4–86.0) 0.61 (0.53–0070)
Health status
Good to very good 95.2 (92.9–97.5) 64.6 (55.7–73.4) 88.4 (85.1–91.8) 82.6 (74.8–90.4) 0.65 (0.58–0.71)
Very bad to fair 89.1 (83.7–94.5) 69.1 (58.9–79.3) 80.3 (73.3–87.3) 81.8 (72.5–91.0) 0.60 (0.51–0.69)
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good overall and in all subgroups except for women born in non-EU
countries where it was excellent. The NPV was above 80% in all
subgroups but fair for women aged 60–69 years and those with mid-
dle educational level.
The results of the multivariate logistic are shown in table 4.
Inaccurate self-reported mammography uptake is more common
among women born in a non-EU country (OR¼ 2.81, 95% CI:
1.54–5.13), people with a high household income (OR¼ 1.27, 95%
CI: 1.02–1.60) and those reporting very bad to fair perceived health.
Discussion
The main objective of this study was to assess the validity in terms of
selection and reporting bias of self-reported mammography uptake
in the BHIS. In the BHIS as in other interview surveys, the validity of
self-reported information depends both on the selection and report-
ing bias. Our results indicate that the mammography uptake in the
BHIS is significantly affected by both types of biases. Therefore,
cautiousness is needed when using self-reported estimates as the
sole method to quantify mammography coverage.
Due to the compulsory nature of the Belgian health insurance and the
fact that the Belgian federal and regional governments signed a protocol
agreement in 2001 for an organized screening program for women aged
50–69 years, to be organized by the regional government with appropri-
ate financial resources supplied by the federal government, it can be
stated that indicators based on the BCHI are quite reliable.
We found a significant selection bias. The relative overestimation
of self-reported information was 9% overall.
Mammography uptake is also significantly affected by reporting
bias in the same direction and in a comparable manner. Indeed, the
relative overestimation of the percentage from the BHIS is 8% over-
all. This significant overestimation is observed across subgroups.
Theoretically, the over-reporting could be partially due to an incom-
plete recording in the BCHI,5,39 but this is highly unlikely because
for the financial management of the health insurance accurate data
are essential. Therefore, administrative mistakes made by health in-
surance employees can be considered to be negligible. Another po-
tential explanation is the underestimation of the timeframe since the
last exam. This phenomenon, also called ‘telescoping’ (i.e. remem-
bering that an event occurred more recently than it actually did), is
the most consistent finding among studies comparing self-reports
with medical or administrative data sources.12,20,40
The poor specificity found in our study (<70%) suggesting a
higher rate of false positives could confirm the hypothesis of tele-
scopic bias. We found that the telescopic bias represents almost half
of the false positive cases. Indeed, if the time frame was moved from
2 to 3 years, the specificity would have been 83%. Over-reporting
may also occur because adhesion to screening recommendations is
perceived to be socially desirable.12 As opposed to findings in the
literature,6,13 our results did not show that over-reporting mam-
mography uptake occurred more often among women with a lower
socioeconomic status. On the contrary, our results suggested that
women with high household income level are more likely to inaccur-
ately report (over-report) their mammography uptake.
When adjusted for other variables, women born in a non-EU
country are more likely to inaccurate report (over-report) their
mammography uptake as opposed of results from tables 2 and 3.
In the complete case analysis (results not shown), only the place
of birth was significantly associated with inaccurate report of mam-
mography uptake, probably because of loss of power due to drop
out of missing values. Although the other variables were not signifi-
cantly associated with the outcome, the direction of the effect
remains unchanged as in analysis after multiple imputation.
Other validation studies have found results that are in line with
those in our study. In their meta-analysis, Howard et al.12 estimated
the pooled sensitivity and the pooled specificity to 95% and 62%,
respectively. In another meta-analysis, Anderson et al. 5 also found
excellent sensitivity (96%) but moderate specificity (61%). In an-
other study, the specificity was much lower (45%) while the sensi-
tivity was comparable.40 The authors explained this difference by the
higher underestimation of the time elapsed since the last exam.
An important advantage of our study compared to most other
studies is the fact that it was conducted in a representative sample of
the population. The most common data used as gold standard in
validation studies are medical records,12,32,40 which can be consid-
ered as more accurate than administrative data. However, medical
data could be too difficult and expensive to obtain for population
estimates. In our context, the use of administrative data as the gold
standard is acceptable since they give exhaustive and accurate infor-
mation on the number of mammograms that are carried out.
Therefore, similar measures of validity (sensitivity, specificity) can
be used as in studies that used medical records data as gold standard.
The overall agreement (84.4%—result not shown) and the kappa
statistic (0.63) as measures of reliability observed in our study were
comparable to those in other studies.32,40
Another important strength of the current study is that we
assessed concomitantly the selection and the reporting bias.
Some limitations of this study need to be highlighted. First, no
distinction could be made between mammograms as part of a
screening program and opportunistic mammograms in the BHIS.
Moreover, because opportunistic screening mammograms are often
miscoded as diagnostic mammograms for reimbursement purposes
in the BCHI, we were unable to distinguish screening mammograms
from diagnostic mammograms. However, since the proportion of
diagnostic mammograms among all mammograms is quite low, the
rate of mammograms outside the screening is an acceptable proxy of
the opportunistic screening. So, the actual indicator that was
assessed was ‘having had mammograms’, including both screening
and opportunistic mammograms. The share of each type has never
been measured in Belgium. In this study, we assumed that the largest
part of the mammograms undergone between 50 and 69 is made for
screening purposes, and therefore we used this information as a
proxy of the breast cancer screening. Second, only a subpopulation
of the BHIS participants (women aged 50–69 years) is analyzed.
Ideally, a re-calibration of sample weights will be optimal.
Unfortunately, because of the limited number of demographic var-
iables in the reference dataset, this was not possible. Third, although
it may seem more logical if we would have compared estimates
Table 4 Adjusted odds ratios (with 95% CI) of inaccurate self-
reported mammography uptake in the past 2 years (defined as
over-reporting or under-reporting). Results of multivariate logistic
regression, Belgium 2013
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obtained in the BHIS with screening information from the complete
population, the data protection authority does not allow the use of
exhaustive information from the BCHI if equally reliable informa-
tion can be obtained from the EPS. As the EPS is a large sample and
selected through a random procedure, it can be assumed that the
EPS estimates perfectly match the indicators that would have been
obtained from the total population.
This study has implications for public health policy-makers. Self-
reported mammography uptake is not the most accurate method to
track the national screening coverage rate and to determine the adher-
ence to the national or international guidelines or attainment of goals.
Therefore, the self-reported mammography uptake should be inter-
preted with caution and when possible objective data should be used.
Despite the moderate validity of mammography uptake in the
BHIS, this data source still has an added value since it provides
information on the socio-demographic determinants of the mam-
mography attendance, and the link with health behaviors and other
health outcomes.
Conclusions
In the BHIS as in other interview surveys, the validity of self-
reported information depends both on the selection and reporting
bias. Our results indicate that the mammography uptake in the
BHIS is significantly affected by both types of biases. Therefore,
cautiousness is needed when using self-reported estimates as the
sole method to quantify mammography coverage. Despite the mod-
erate validity of mammography uptake in the BHIS, this data source
still has an added value since it provides information on the socio-
demographic determinants of the mammography attendance, and
the link with health behaviors and other health outcomes. Further
dedicated studies are needed to confirm our findings.
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